Bispecific antibody platform capable of simultaneously acting on two different target proteins
AffiMab allows for rapid development of bispecific antibodies that can neutralize two different target proteins at the same time.
AffiMab combines the advantages of monoclonal antibodies and Affibody technology. The platform
allows for engineering a bispecific antibody with affinity for two different target proteins.
Bispecific antibodies demonstrate superior therapeutic effect compared to monoclonal antibody
treatments in refractory diseases. Furthermore, AffiMab demonstrates high molecular stability
in vivo and excellent production yields.